Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement

Drug Development and Industrial Pharmacy

Volumn 37, Issue 1, 2011, Pages 8-14

  Muchow, M ^a,b   Maincent, P ^b   Mller, R H ^a   Keck, C M ^a,c  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITÉ DE LORRAINE   (France)

^c UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

DSC; Lipid nanoparticles; NLC; Oral bioavailability; Testosterone undecanoate

Indexed keywords

ANDRIOL TESTOCAPS; CARRIER PROTEIN; TESTOSTERONE UNDECANOATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; IN VIVO STUDY; LIGHT SCATTERING; MALE; NONHUMAN; PARTICLE SIZE; RAT; SINGLE DRUG DOSE; X RAY DIFFRACTION; ZETA POTENTIAL;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG CARRIERS; DRUG STABILITY; LIPIDS; NANOSTRUCTURES; PARTICLE SIZE; TESTOSTERONE; X-RAY DIFFRACTION;

EID: 78650034197     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.489559     Document Type: Article

References (27)

1. Foye WO, Lemke TL, Williams DA. (2007). Foye's principles of medicinal chemistry, 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins.
2. Frey H, Aakvaag A, Saanum D, Falch J. (1979). Bioavailability of oral testosterone in males. Eur J Clin Pharmacol, 16:345-9.
3. Johnsen SG. (1978). Long-term oral testosterone and liver function. Lancet, 1:50.
4. Köhn FM, Schill WB. (2003). A new oral testosterone undecanoate formulation. World J Urol, 21:311-5.
5. Shackleford DM, Faassen WA, Houwing N, Lass H, Edwards GA, Porter CJ, et al. (2003). Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. J Pharmacol Exp Ther, 306:925-33.
6. Bagchus WM, Hust R, Maris F, Schnabel PG, Houwing NS. (2003). Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy, 23:319-25.
7. Schnabel PG, Bagchus W, Lass H, Thomsen T, Geurts TB. (2007). The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps. Clin Endocrinol (Oxf), 66:579-85.
8. Hanafy A, Spahn-Langguth H, Vergnault G, Grenier P, Tubic Grozdanis M, Lenhardt T, et al. (2007). Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev, 59:419-26.
9. Liversidge GG, Conzentino P. (1995). Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm, 125:309-13.
10. Liversidge GG, Cundy KC. (1995). Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm, 125:91-7.
11. Charman WN. (2000). Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J Pharm Sci, 89:967-78.
12. Porter CJ, Charman WN. (2001). Lipid-based formulations for oral administration: Opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs. J Recept Signal Transduct Res, 21:215-57.
13. Müller RH, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto EB. (2006). Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm, 317:82-9.
14. Penkler L, Müller RH, Runge S, Ravelli V. (2003). Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation. US patent no. 6,551,619.
15. Müller RH. (1996). Zetapotential und Partikelladung in der Laborpraxis. Stuttgart: Wissenschaftliche Verlagsges.
16. Lucks JS, Müller BW, Müller RH. (1990). Inorganic suspensions - interaction with salts and ionic surfactants. Int J Pharm, 58:229-35.
17. Charman WN, Porter CJH. (1996). Lipophilic prodrugs designed for intestinal lymphatic transport. Adv Drug Deliv Rev, 19:149-69.
18. Porter CJ, Charman WN. (2001). Intestinal lymphatic drug transport: An update. Adv Drug Deliv Rev, 50:61-80.
19. Muchow M, Maincent P, Müller RH. (2008). Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm, 34:1394-405.
20. Müller RH, Mäder K, Lippacher A, Jenning V. (2000). Fest-flüssige (halbfeste) Lipidpartikel und Verfahren zur Herstellung hochkonzentrierter Lipidpartikeldispersionen. PCT/EP00/ 04565.
21. Müller RH, Radtke M, Wissing SA. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev, 54:S131-55.
22. Kutz G. (2001). Kosmetische Emulsionen und Cremes. Augsburg: Verlag für Chemische Industrie.
23. Muchow M. (2009). Nanostructured carriers for oral drug delivery. PhD thesis, Freie Universität, Berlin, in preparation.
24. Olbrich C, Kayser O, Müller RH. (2002). Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)-effect of surfactants, storage time and crystallinity. Int J Pharm, 237:119-28.
25. Olbrich C, Mehnert W, Müller RH. (1998). In vitro degradation properties of solid Lipid nanoparticles SLN™ 2nd world meeting on pharmaceutics, biopharmaceutics, pharmaceutical technology, APGI/APV, Paris, France, May 25-28.
26. Olbrich C, Müller RH. (1999). Enzymatic degradation of SLNeffect of surfactant and surfactant mixtures. Int J Pharm, 180:31-9.
27. Junghanns JU, Müller RH. (2008). Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine, 3:295-309.